This trial is evaluating whether LungTalk will improve 1 primary outcome in patients with Smoking. Measurement will happen over the course of 6 months.
This trial requires 150 total participants across 1 different treatment group
This trial involves a single treatment. LungTalk is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
"About 23,000 people get lung cancer each year. People with smoking-related lung cancer appear to have higher mortality rates than those without. In addition, female gender and black race are independent risk factors for lung cancer and mortality." - Anonymous Online Contributor
"Laryngeal cancer is a rare malignancy with an excellent long-term prognosis, although long-term survival in the elderly is rarely reported. The best management of lung cancer remains controversial. Lung cancer with extrapulmonary spread to locoregional disease is highly treatable. However, lung cancer with distant metastasis with a tendency for a prolonged survival is rarely cured with chemotherapy, although survival may extend beyond five years." - Anonymous Online Contributor
"Symptoms of lung cancer include coughing up blood, shortness of breath, weight loss, indrawing of the chest and loss of appetite. A physical examination should also reveal a lump on the chest.\n" - Anonymous Online Contributor
"Treatment of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) will depend on your personal cancer history and stage at diagnosis. Some treatment options are surgery, chemotherapy, and targeted therapy like gefitinib and erlotinib. For lung cancer patients, proper staging to diagnose and treat their cancer may improve the outcome." - Anonymous Online Contributor
"Lung cancer is caused by a combination of factors in which a predisposition to it is present and the tumor requires a specific trigger for it to express itself. It is probable that a genetic basis for lung cancer is not present in humans. The lung cancer susceptibility gene(s) will be elucidated in the first few years of this Century." - Anonymous Online Contributor
"Although there may be significant differences of the histology of various subtypes of lung cancer, they are not always identifiable on a pathological examination, and many histological type specific features cannot be clearly defined. Therefore, pathologists have made a distinction between what is lumped together as'solid tumors' and what is lumped together as'seam/cystic lesions' in both lung cancer and other tumours. The solid lung tumour can include one or another histological subtypes. These subtypes do not behave in a predictable, neat way. They may behave as a single'solid tumor' or may more often behave as a collection of related types." - Anonymous Online Contributor
"Lungtalk has been used in a number of clinical trials. A review of the published trial results will give an idea of its efficacy as well as its side effects. There was high consistency in the way trials were conducted, which is a good quality indicator that can be used to validate clinical trial reports. Lungtalk has been shown to be safe and effective. It also has a long duration of action. It is worthwhile to see if lungtalk has the same benefit as other modalities in the future." - Anonymous Online Contributor
"Patients feel comfortable with the notion that they themselves must bear the emotional burden of communicating. Lung tumor patients can be encouraged to discuss their tumor with their families if they wish. However, it is also very important for the patient and his/her family to know that, in this sense, such conversations can actually be comforting to them. Patients should also be aware of other side-effects in which they may notice an increased risk, such as impaired speech. We recommend counseling of patients about the possibility of decreased speech, to which patients might reply, 'Indeed, how can I be sure?', implying the need for reassurance." - Anonymous Online Contributor
"The occurrence of lung cancer in families suggests that genetic factors play a role and may be detectable in the first or second degree relatives of affected patients with lung cancer. The lung cancer gene in this case must be more widespread in the population than it is to explain any of the observed results. The gene must also be inherited in a manner such that risk is elevated in the male or female carrier, relative to the control population." - Anonymous Online Contributor
"Overall survival depends on the tumor stage, and it varies depending on the cancer type. Even metastatic small cell cancers have a high survival rate, while sarcoma is the only cancer which has worse survival rates compared to small cell lung cancer. Also metastatic squamous cell carcinoma may have a higher survival rate than metastatic adenocarcinoma. The stage IB NSCLC seems the most favorable, the stage IC-NOS the worst, especially in patients with poor general health who have an increased risk of death." - Anonymous Online Contributor
"As of November 2, 2013 NCI had been conducting a comprehensive review of key clinical lung cancer trials that showed lung cancer patients treated with gemcitabine, a chemotherapy drug, had a 15% increased risk for death compared to those treated with placebo; in addition, gemcitabine appears to cause serious adverse effects. Thus, NCI reported that clinical research evaluating investigational lung cancer treatments is not sufficient to guide clinical practice, that its conclusions may be biased towards trial designs that favour testing the newest treatments, that the trials currently under way may mislead clinicians and may be unnecessarily costly and time-consuming, and that most trials were small and did not meet key quality metrics outlined by NCI." - Anonymous Online Contributor
"Lung cancer is a disease with onset occurring in people around 40 yr of age accounting for 95% of the cases reported. The incidence varies in different parts of the world. It is low in low and middle income countries such as Greece, Turkey, and Turkey being higher in South-East Asia, Africa, Arabia and Latin America. In China and India the rate has been increasing. This is due to increasing industrialization in some countries, as in India. But even in low and middle income countries such as India the mortality is high and about 20/ 100,000 persons die before age 65 yr." - Anonymous Online Contributor